CLS TRANBERG®|Thermo Therapy System is evaluated for treatment of vascular malformations by a hospital in the US
Clinical Laserthermia Systems (CLS) (publ), announced on 20 October 2017 that the company through its subsidiary CLS Americas Inc. signed a supplier agreement with a hospital in the US. The agreement means that CLS is an approved supplier to the hospital, which is a prerequisite for the company when delivering equipment. The hospital has initially used the delivered TRANBERG product for treatment of symptomatic painful non-malignant vascular malformations positioned in torso and extremities.
- As previously announced two patients have received treatment. An image guided laser treatment procedure was carried out, aiming at reducing pain and decreasing /eliminating the vascular malformation, with an immediate positive outcome. Apart from being able to offer patients an efficient and gentle treatment, the objective is also, as previously stated, to provide the physician with the opportunity to publish the results of the ongoing work, said Dan Mogren, Chief Commercial Officer at CLS
CLS has for some time collaborated with the hospital’s department of interventional radiology, which has extensive activities in the area of image guided minimal invasive treatment of tumor diseases. The objective of the collaboration is to evaluate and further develop CLS’ immunostimulating treatment, imILT® as well as MR-guided laser ablation.
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 23 October 2017, at 03:40 PM.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: firstname.lastname@example.org
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se